The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
Abstract
OBJECTIVE: Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: The efficacy (HbA1c and glucose) and safety (serum aminotransferase) of once-daily oral administration of LY2409021 was assessed in two double-blind studies. Phase 2a study patients were randomized to 10, 30, or 60 mg of LY2409021 or placebo for 12 weeks. Phase 2b study patients were randomized to 2.5, 10, or 20 mg LY2409021 or placebo for 24 weeks. RESULTS: LY2409021 produced reductions in HbA1c that were significantly different from placebo over both 12 and 24 weeks. After 12 weeks, least squares (LS) mean change from baseline in HbA1c was –0.83% (10 mg), –0.65% (30 mg), and –0.66% (60 mg) (all P < 0.05) vs. placebo, 0.11%. After 24 weeks, LS mean change from baseline in HbA1c was –0.45% (2.5 mg), –0.78% (10 mg, P < 0.05), –0.92% (20 mg, P < 0.05), and –0.15% with placebo. Increases in serum aminotransferase, fasting glucagon, and total fasting glucagon-like peptide-1 (GLP-1) were observed; levels returned to baseline after drug washout. Fasting glucose was also lowered with LY2409021 at doses associated with only modest increases in aminotransferases (mean increase in alanine aminotransferase [ALT] ≤10 units/L). The incidence of hypoglycemia in the LY2409021 groups was not statistically different from placebo. CONCLUSIONS: In patients with type 2 diabetes, glucagon receptor antagonist treatment significantly lowered HbA1c and glucose levels with good overall tolerability and a low risk for hypoglycemia. Modest, reversible increases in serum aminotransferases were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Baron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
Conarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110
Self-citation
Research works printed but not linked: 27
- Woerle, 2006, Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes, Am J Physiol Endocrinol Metab, 290, E67, 10.1152/ajpendo.00529.2004 · DOI
- Sloop, 2005, Glucagon as a target for the treatment of type 2 diabetes, Expert Opin Ther Targets, 9, 593, 10.1517/14728222.9.3.593 · DOI
- Hollander, 1982, Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man, Diabetes, 31, 489, 10.2337/diab.31.6.489 · DOI
- Ward, 1984, Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man, J Clin Endocrinol Metab, 58, 449, 10.1210/jcem-58-3-449 · DOI
- Gastaldelli, 2000, Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study, Diabetes, 49, 1367, 10.2337/diabetes.49.8.1367 · DOI · Paper page
- Shah, 2000, Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus, J Clin Endocrinol Metab, 85, 4053
- Bagger, 2011, Glucagon antagonism as a potential therapeutic target in type 2 diabetes, Diabetes Obes Metab, 13, 965, 10.1111/j.1463-1326.2011.01427.x · DOI
- Tham, 2011, The glucagon receptor antagonist LY2409021 attenuates increases in hepatic glucose output (HGO) and blood glucose during hyperglucagonemia in healthy male patients (Abstract 416-PP), Diabetes, 60, A115
- Kelly, 2015, Glucagon receptor antibody LY2786890 reduced glucose levels in type 2 diabetes mellitus patients (Abstract 106-LB), Diabetes, 64, LB27
- Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) (Abstract 309-OR), Diabetes, 60, A85
- Ruddy, 2011, Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy of a glucagon receptor antagonist, MK-0893, in type 2 diabetes (T2DM) (Abstract 311-OR), Diabetes, 60, A85
- Kazierad, 2015, Pharmacokinetics (PK) and pharmacodynamics (PD) of PF-06291874 (PF), a glucagon receptor antagonist, in subjects with T2DM (Abstract 1202-P), Diabetes, 64, A310
- Vajda, 2015, Pharmacokinetics and pharmacodynamics of the glucagon receptor antagonist LGD-6972 in a multi-dose clinical trial (Abstract 1193-P), Diabetes, 64, A308
- Morgan, 2014, ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy (Abstract 109-LB), Diabetes, 63, LB28
- Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
- Sloan, 2012, A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon, Clin Biochem, 45, 1640, 10.1016/j.clinbiochem.2012.07.111 · DOI
- Petersen, 2001, Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans, Diabetologia, 44, 2018, 10.1007/s001250100006 · DOI · Paper page
- Whalley, 2011, Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells, J Endocrinol, 211, 99, 10.1530/JOE-11-0094 · DOI · Paper page
- Longuet, 2013, Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor, Diabetes, 62, 1196, 10.2337/db11-1605 · DOI · Paper page
- Ali, 2011, Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis, J Clin Invest, 121, 1917, 10.1172/JCI43615 · DOI
- Gu, 2010, Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor, Am J Physiol Endocrinol Metab, 299, E624, 10.1152/ajpendo.00102.2010 · DOI
- Lefèbvre, 2015, Inhibiting or antagonizing glucagon: making progress in diabetes care, Diabetes Obes Metab, 17, 720, 10.1111/dom.12480 · DOI
- Yu, 2011, Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice, PLoS One, 6, e23397, 10.1371/journal.pone.0023397 · DOI
- Sinclair, 2008, Glucagon receptor signaling is essential for control of murine hepatocyte survival, Gastroenterology, 135, 2096, 10.1053/j.gastro.2008.07.075 · DOI
- Liang, 2004, Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice, Diabetes, 53, 410, 10.2337/diabetes.53.2.410 · DOI · Paper page
- Hancock, 2010, Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice, Mol Endocrinol, 24, 1605, 10.1210/me.2010-0120 · DOI
- Sloop, 2004, Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors, J Clin Invest, 113, 1571, 10.1172/JCI20911 · doi:10.1172/jci20911 · Paper page
Cited by
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,133
Molecular mechanisms of ROS production and oxidative stress in diabetes
Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R., & de Bittencourt, P. I. H. (2016) · Biochemical Journal · doi:10.1042/bcj20160503c · Cited by 878
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Current anti-diabetic agents and their molecular targets: A review
Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.061 · Cited by 369
Insulin Secretion Depends on Intra-islet Glucagon Signaling
Svendsen, B., Larsen, O., Gabe, M. B. N., Christiansen, C. B., Rosenkilde, M. M., Drucker, D. J., & Holst, J. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.018 · Cited by 355
Regulation of glucose and lipid metabolism in health and disease
Chen, L., Chen, X.-W., Huang, X., Song, B.-L., Wang, Y., & Wang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-1563-3 · Cited by 306
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis
Holst, J. J., Wewer Albrechtsen, N. J., Pedersen, J., & Knop, F. K. (2017) · Diabetes · doi:10.2337/db16-0994 · Cited by 187
Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
Perry, R. J., Zhang, D., Guerra, M. T., Brill, A. L., Goedeke, L., Nasiri, A. R., Rabin-Court, A., Wang, Y., Peng, L., Dufour, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2074-6 · Cited by 186
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Guzman, C. B., Zhang, X. M., Liu, R., Regev, A., Shankar, S., Garhyan, P., Pillai, S. G., Kazda, C., Chalasani, N., & Hardy, T. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12958 · Cited by 172
“While several studies with LY2409021 have demonstrated a significant glycaemic-lowering effect in patients with T2D, results have also shown dose-dependent and reversible increases in hepatic aminotransferase levels.(6) The present study was designed to further assess the risk–benefit profile of LY2409021, and to inve…”
ResultSelf-citationThe Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Winther-Sørensen, M., Galsgaard, K. D., Santos, A., Trammell, S. A. J., Sulek, K., Kuhre, R. E., Pedersen, J., Andersen, D. B., Hassing, A. S., Dall, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101080 · Cited by 135
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Wewer Albrechtsen, N. J., Færch, K., Jensen, T. M., Witte, D. R., Pedersen, J., Mahendran, Y., Jonsson, A. E., Galsgaard, K. D., Winther-Sørensen, M., Torekov, S. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-017-4535-5 · Cited by 119
100 years of glucagon and 100 more
Wewer Albrechtsen, N. J., Holst, J. J., Cherrington, A. D., Finan, B., Gluud, L. L., Dean, E. D., Campbell, J. E., Bloom, S. R., Tan, T. M.-M., Knop, F. K., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05947-y · Cited by 117
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Obesity dysregulates fasting-induced changes in glucagon secretion
Stern, J. H., Smith, G. I., Chen, S., Unger, R. H., Klein, S., & Scherer, P. E. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0201 · Cited by 84
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
SMOC1 is a glucose-responsive hepatokine and therapeutic target for glycemic control
Montgomery, M. K., Bayliss, J., Devereux, C., Bezawork-Geleta, A., Roberts, D., Huang, C., Schittenhelm, R. B., Ryan, A., Townley, S. L., Selth, L. A., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8048 · Cited by 63
Alpha cell dysfunction in type 1 diabetes
Yosten, G. L. C. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.001 · Cited by 62
Kazierad, D. J., Bergman, A., Tan, B., Erion, D. M., Somayaji, V., Lee, D. S., & Rolph, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12672 · Cited by 44
Winther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity
Vega, R. B., Whytock, K. L., Gassenhuber, J., Goebel, B., Tillner, J., Agueusop, I., Truax, A. D., Yu, G., Carnero, E., Kapoor, N., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab118 · Cited by 24
Faggionato, E., Tonello, A., Laurenti, M. C., Vella, A., & Dalla Man, C. (2025) · American Journal of Physiology - Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00172.2025
Metadata
- Authors
- Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., Deeg, M. A., Moller, D. E., & Hardy, T. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-12-17
- Volume
- 39
- Issue
- 7
- Pages
- 1241-1249
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2207556001
- Cited by
- 212
- References
- 8
- FWCI
- 16.20
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-06-01)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.